ClinicalTrials.gg
RecruitingNCT06177327TIM-DYSUpdated Feb 29, 2024

Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome

An observational study in Fibrous Dysplasia of Bone, sponsored by Hospices Civils de Lyon. Recruiting at 16 sites in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Primary conditionFibrous Dysplasia, PolyostoticRegistry: Fibrous Dysplasia of BoneReclassifiedWhy we changed it
Registry
Fibrous Dysplasia of Bone — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fibrous Dysplasia, Polyostotic
Why
  1. The study's title name Fibrous Dysplasia, Polyostotic, a narrower term within Fibrous Dysplasia of Bone.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
545
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Fibrous dysplasia of bone /McCune Albright syndrome (FD/MAS) is a rare bone disease caused by somatic mutations in GNAS gene. This GNAS mutation predisposes to cancers, including breast cancer, thyroid cancer, chondrosarcoma and osteosarcoma, as well as biliary tract anomalies, liver-tumors or pancreatic tumors - IPMNs. Intraductal papillary and mucinous neoplasms of the pancreas (IPMN) are cystic intraepithelial ductal lesions developed at the expense of pancreatic ducts. They are pre-cancerous lesions, requiring monitoring and, in case of progression or malignant degeneration, surgical resection. Pancreatic MRI screening of patients with polyostotic FD and MAS is recommended.

The aim of this study is to investigate the epidemiology and characteristics of these hepato-pancreato-biliary abnormalities (prevalence, age of onset, degeneration), based on magnetic resonance imaging (MRI) realized during the follow-up of patients with FD/MAS treated in a French FD expert center.

A better understanding of these IPMNs and other digestive abnormalities will enable clinicians to improve the management and monitoring in this high-risk population.

02

Conditions studied

  • Fibrous Dysplasia of Bone

Browse trials for

Keywords

  • Fibrous dysplasia of bone
  • McCune Albright syndrome
  • pancreatic neoplasms
  • IPMN
03

In context

Fibrous Dysplasia, Polyostotic Reclassified

23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.

Browse Fibrous Dysplasia, Polyostotic studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Compared within Fibrous Dysplasia, Polyostotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrous Dysplasia of Bone. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years with polyostotic FD/MAS
  • Followed up in the national FD reference center (Lyon) or in a FD French expert center: Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Lille, Marseille, Montpellier, Nice, Paris, Poitiers, Rennes, Saint-Etienne, Strasbourg.
  • who had an hepato-bilio-pancreatic MRI during their follow-up, since January 2002
  • No objection to data collection

Exclusion criteria

Exclusion Criteria:

-Opposition to data collection

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
545 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with polyostotic fibrous dysplasia McCune Albright syndrome

    A retrospective data collection and statistical analyses will be performed. Adults with polyostotic fibrous dysplasia McCune Albright syndrome, who underwent an hepato-bilio-pancreatic MRI since January 2002, during their follow-up

    Other: Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.

Interventions

  • OtherScreening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.

    Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome

06

What researchers measure

Primary outcomes

  1. Describe hepato-bilio-pancreatic abnormalities in FD/MAS and estimate the prevalence of IPMN.

    Hepato-bilio-pancreatic abnormalities (size, number, complications) will be described based on hepato-bilio-pancreatic MRI.

    Time frame: hepato-bilio-pancreatic MRI performed from January 2002 until December 2024.

07

Study locations

1 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 20, 2023
StartActual
Jan 19, 2024
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 12, 2025
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06177327
Responsible party
Sponsor
First posted
Dec 20, 2023
Start date
Jan 19, 2024
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 12, 2025 (estimated)
Last update
Feb 29, 2024

Study contacts

Roland Chapurlat, MD, PhD
Contact
roland.chapurlat@chu-lyon.fr
+ 33 (0)4 72 11 74 82
Mélanie Legrand, MD
Contact
melanie.legrand@chu-lyon.fr
+ 33 (0)4 72 11 74 79

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion